SuperworthCareDx profit margin CDNA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2013.
- Net margin, 12 months
- 24.2%
- Operating margin, 12 months
- 23.6%
- Net margin on a year earlier
- +7.2 pts
- Peer median
- 9.3%
Over the twelve months to Jun 30, 2026, CareDx kept 24.2% of its revenue as net profit, with an operating margin of 23.6% and a gross margin of 70.6%.
Five years earlier its net margin was −3.5%.
The median for 10 diagnostics and research stocks of a similar size is 9.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −5.6% | −8.1% | 67.6% |
| FY2024 | 15.7% | 12.2% | 67.1% |
| FY2023 | −67.9% | −72.5% | 63.6% |
| FY2022 | −23.8% | −24.0% | 65.1% |
| FY2021 | −10.3% | −10.0% | 67.1% |
| FY2020 | −9.7% | −11.7% | 67.2% |
| FY2019 | −17.3% | −19.3% | 64.2% |
| FY2018 | −61.1% | −20.3% | 56.9% |
| FY2017 | n/a | −42.0% | 55.8% |
| FY2016 | −97.1% | −91.9% | 48.0% |
| FY2015 | −48.7% | −42.4% | 63.5% |
| FY2014 | 2.9% | 4.6% | 68.7% |
| FY2013 | −16.0% | −3.9% | 58.9% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 24.2% | +7.2 pts | 23.6% | |
| Q1 FY26 | −2.0% | −19.9 pts | −3.9% | |
| Q4 FY25 | −5.6% | −21.4 pts | −8.1% | |
| Q3 FY25 | 19.7% | +68.7 pts | 16.7% | |
| Q2 FY25 | 17.1% | +73.0 pts | 13.5% | |
| Q1 FY25 | 17.9% | +85.7 pts | 14.4% | |
| Q4 FY24 | 15.7% | +83.6 pts | 12.2% | |
| Q3 FY24 | −49.0% | −18.5 pts | −53.2% | |
| Q2 FY24 | −55.9% | −28.8 pts | −61.0% | |
| Q1 FY24 | −67.8% | −42.5 pts | −73.3% | |
| Q4 FY23 | −67.9% | −44.1 pts | −72.5% | |
| Q3 FY23 | −30.5% | −7.1 pts | −33.6% |
Against its peers
Companies in Medical - Diagnostics & Research nearest CareDx's size, closest first, today.
| Company | Profit margin |
|---|---|
| CDNACareDx | 24.2% |
| VCYTVeracyte | 20.4% |
| BLLNBillionToOne | 9.5% |
| LNTHLantheus | 17.7% |
| CAICaris Life Sciences | 10.6% |
| BIOBio-Rad Laboratories | 8.6% |
| RVTYRevvity | 8.2% |
| MEDPMedpace | 17.7% |
| NRCNRC Health | 4.2% |
| LHLabcorp | 7.0% |
| DGXQuest Diagnostics | 9.2% |
| Peer median | 9.3% |
Where CareDx ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on CareDx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.